American Society of Hematology: Benefits Last for Nilotinib in CML, University of Bologna Study

Published: Dec 07, 2010

MedPageToday -- ORLANDO -- The second-generation tyrosine kinase inhibitor nilotinib (Tasigna) had long-lasting benefits in chronic myeloid leukemia with the Philadelphia chromosome, according to the results of a phase II study reported here. After three years of daily treatment with the drug, only one of 73 CML patients had progressed to blast crisis and subsequently died of the disease, said Gianantonio Rosti, MD, of the University of Bologna in Bologna, Italy.

Back to news